4-Nitroestrone 3-methyl ether been shown in this laboratory to be a potent growth inhibitor of the MXT mouse mammary tumor and the DMBA-induced rat mammary tumor in intact and ovariectomized animals. It is the purpose of this proposal to obtain information which may aid in the determination of the mechanism by which this non-toxic compound brings about regression in hormone dependent mammary tumors. Since 4-nitroestrone 3-methyl ether was initially designed as a specific inhibitor of estrogen sulfotransferase, experiments are planned which will indicate whether the blockage of this mammary tumor enzyme is related to tumor regression, whether the receptor mechanism is involved, or whether tumor regression is the result of periferal influences of this agent. Furthermore since this polar A-ring substituted estrogen exhibits only a modest capacity to enter target tissue, new less polar derivatives will be synthesized which are more amenable to tissue uptake, are capable of inhibiting the sulfotransferase, but are not able to be dealkylated in vivo to form metabolites which interact with receptors. 4-Nitroestrone 3-methyl ether and other A-ring substituted estrogens [in general the 2 and 4-substituted estrogens, their 3-O-alkyl ethers or 3-O-(Alpha, Beta, Gamma-hydroxyalkyl) ethers and 2 or 4-substituted estra-1,3,5(10)-triene-17-one compounds] will be tested in various experimental tumor systems (e.g. DMBA-and NMU-induced breast cancer in rats, the MXT hormone dependent ductal carcinoma, the 16/c and 13/c hormone independent mouse mammary tumors, the MX-1 human tumor and MCF-7 human breast cancer cells in athymic mice).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA037387-03
Application #
3175254
Study Section
Biochemical Endocrinology Study Section (BCE)
Project Start
1984-04-01
Project End
1987-03-31
Budget Start
1986-04-01
Budget End
1987-03-31
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
Schools of Medicine
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Brooks, Sam C; Skafar, Debra F (2004) From ligand structure to biological activity: modified estratrienes and their estrogenic and antiestrogenic effects in MCF-7 cells. Steroids 69:401-18
Wiese, T E; Polin, L A; Palomino, E et al. (1997) Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study. J Med Chem 40:3659-69
Wiese, T E; Dukes, D; Brooks, S C (1995) A molecular modeling analysis of diethylstilbestrol conformations and their similarity to estradiol-17 beta. Steroids 60:802-8
Davis, M D; Butler, W B; Brooks, S C (1995) Induction of tissue plasminogen activator mRNA and activity by structurally altered estrogens. J Steroid Biochem Mol Biol 52:421-30
Palomino, E; Heeg, M J; Horwitz, J P et al. (1994) Skeletal conformations and receptor binding of some 9,11-modified estradiols. J Steroid Biochem Mol Biol 50:75-84
Wiese, T E; Brooks, S C (1994) Molecular modeling of steroidal estrogens: novel conformations and their role in biological activity. J Steroid Biochem Mol Biol 50:61-73
VanderKuur, J A; Brooks, S C (1994) Effect of A-ring isomers of estradiol-17 beta on gene products in MCF-7 cells. Steroids 59:548-54
VanderKuur, J A; Wiese, T; Brooks, S C (1993) Influence of estrogen structure on nuclear binding and progesterone receptor induction by the receptor complex. Biochemistry 32:7002-8
Wiese, T E; Kral, L G; Dennis, K E et al. (1992) Optimization of estrogen growth response in MCF-7 cells. In Vitro Cell Dev Biol 28A:595-602
Palomino, E; Heeg, M J; Horwitz, J P et al. (1990) Binding, X-ray and NMR studies of the three A-ring isomers of natural estradiol. J Steroid Biochem 35:219-29

Showing the most recent 10 out of 16 publications